Antiretroviral therapy benefits HIV/hepatitis C coinfected patients
AIDScienceThe replication of hepatitis C virus (HCV) is not inhibited by highly active antiretroviral therapy (HAART), and treatment-related hepatotoxicity is common. Researchers in Germany studied liver-related mortality and overall mortality in a group of 285 patients, to clarify the effect of HAART in HIV/HCV-coinfected patients. They found that in addition to improved overall survival, HAART therapy significantly reduced long-term liver-related mortality, and that in these patients the survival benefit seemed to outweigh by far the associated risks of severe hepatotoxicity. Source: The Lancet 2003; 362: 1708-13.
—Posted: December 8, 2003
More news headlines: This week | Last week | Search archive